J. Middeke

Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.

Relapsed or refractory acute myeloid leukemia (R/R AML) remains a therapeutic challenge, with standard high‑dose cytarabine-based salvage regimens achieving complete remission (CR) rates of around 50%. In the phase 1/2 RELAX trial, adding venetoclax (VEN) to high‑dose cytarabine and mitoxantrone (HAM) was considered sa...

Multimodal Artificial Intelligence Fusion Models to Predict Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia

Retrieval-Augmented Large Language Models for Clinically Aligned Adverse Event Coding in Acute Myeloid Leukemia Clinical Trials

Evaluation across three AML clinical trials showed that strict LLT-level string agreement underestimated clinical ap-propriateness, highlighting the importance of combining hierarchical evaluation metrics with clini-cal expert validation for AI-assisted MedDRA coding in hematology trials.

Benchmarking ten frontier large language models on 1,477 board style multiple choice questions in hematology

Large Language Models (LLMs) are increasingly used by clinicians and patients for medical queries, yet their accuracy and safety at the specialist level in hematology remain insufficiently characterised. We benchmarked ten frontier proprietary and open-weight LLMs across two generations on 1,477 board-style hematology...